item management s discussion and analysis of financial condition and results of operation the following discussion and analysis provides information which management believes is relevant to an assessment and understanding of the company s results of operations and financial condition 
the discussion should be read in conjunction with the audited consolidated financial statements of the company and notes thereto 
this report contains certain statements of a forward looking nature relating to future events or the future financial performance of the company 
investors are cautioned that such statements are only predictions and that actual events or results may differ materially 
in evaluating such statements  investors should specifically consider the various factors identified in this report which could cause actual results to differ materially from those indicated by such forward looking statements  including the matters set forth in business additional risk factors 
overview the company s sales to date have consisted primarily of sales of products used for research purposes and imaging systems 
sales of products for diagnostic use require fda approval 
as a result  analysis of past sales of products for research use are not necessarily indicative of future sales of products for diagnostic purposes 
in may  the company acquired the imaging line of business of biological detections systems  inc bds 
the aggregate purchase price of million was paid in cash  notes and common stock of the company 
in september  the company acquired of the outstanding stock of appligene  headquartered in strasbourg  france 
the aggregate purchase price of million was paid in cash  notes and common stock of the company 
the acquisitions of appligene and the imaging line of business of bds in together  the acquisitions were accounted for as purchases and accordingly  the consolidated results of operations for the company include the results of these acquired businesses from their respective dates of acquisition 
the company attributed approximately million and million of the purchase prices of the imaging line of business of bds and of appligene  respectively  to the value of acquired research and development projects in progress 
accordingly  such amounts were expensed by the company at their respective dates of acquisition 
a significant amount of the company s sales in europe are as a result of the appligene acquisition 
approximately million of the purchase price of bds was allocated to intangible assets  and such amount is being amortized over five years 
approximately million of the purchase price of appligene was allocated to intangible assets and is being amortized on a straight line method over periods of two to ten years  with a weighted average amortization period of eight years 
see note of the notes to consolidated financial statements 
in october  oncormed previously an owned consolidated subsidiary of the company  completed an initial public offering of its common stock which reduced the company s ownership interest in oncormed to approximately 
accordingly  the results of operations of oncormed were accounted for on the equity method of accounting retroactive to january   resulting in a non operating expense of million for the company s proportionate share of oncormed s losses in in addition  the company increased its carrying value of its investment in oncormed by million to an amount equal to the company s proportionate share of the recorded stockholders equity of oncormed at the completion of the initial public offering 
the adjustment was credited directly to the stockholders equity of the company in the fourth quarter of in february  oncormed completed a public offering of its common stock which reduced the company s ownership interest in oncormed to approximately 
the company will increase its carrying value of its investment in oncormed by approximately million to an amount equal to the company s proportionate share of the recorded stockholders equity of oncormed at the completion of the offering and credit the adjustment directly to stockholders equity in the first quarter of the company will continue to record its proportionate share of the results of operations of oncormed  expected to be losses throughout  adjusting the carrying value of the investment and advances until such time that the carrying value and advances are eliminated 
in june  the company formed oncorpharm  a consolidated subsidiary  to develop and commercialize therapeutic products using oncor s technologies in the field of genetic repair and drug delivery 
oncorpharm was initially capitalized with a  capital contribution from the company and has subsequently raised  in a private placement 
the company has advanced approximately  to oncorpharm which amount was converted into oncorpharm common stock at per share 
results of operations consolidated product sales increased to million in compared to million in  which represented a increase from million in in each period  sales increases in the company s core business units more than offset significant declines in the sale of industrial imaging systems 
industrial imaging sales were million  million  and million in   and  respectively 
the company is actively pursuing the divestiture of that business unit 
the net increase in sales in as compared to is attributable to increases in product sales in europe through the company s french subsidiary  appligene 
the net increase in sales in compared to was due to revenues generated by appligene  which was acquired in september  and the release of new products 
in  appligene accounted for million of the sales increase occurring since the date of its acquisition in september the sale of probes and reagents increased by million in compared to  due largely to the development and commercialization of new products 
contract and grant revenue increased to million in from million in two grants were received from the national institutes of health  one in the middle of and the other early in the grant proceeds are earned over two year periods  during which periods grant revenue is recorded as the research work progresses 
the underlying contracts and grants expire in and extensions of the grants are being pursued  but no assurance of extension can be made 
contract and grant revenue was not significant in gross profit as a percent of sales increased to in from in  which represented a decrease from in the increase in over was due to favorable product mix and to increased sales in europe which support higher margins 
the margin in was higher than in because of the relatively high amount of sales of higher profit margin industrial imaging products and of the favorable effect of spreading fixed manufacturing costs over higher production levels 
amortization of intangible assets in and was due to the amortization of the portion of the purchase price of appligene attributable to the value of intangible assets acquired  primarily for contracts  completed research projects  and the excess of the purchase price over the book value of the assets acquired 
the intangible assets are being amortized on a straight line basis over periods ranging from two to ten years  with a weighted average period of approximately eight years 
selling  general and administrative expenses increased to in  compared to million in  which represented a increase from million in approximately million of the increase in is attributable to expenses associated with the first full year of the inclusion of appligene 
an additional increase of million in selling  general  and administrative expenses of appligene was due to i depreciation on a new facility  ii higher levels of its sales force  and iii unfavorable exchange rate differences 
an additional million of the increase was due to the general and administrative expenses incurred by the oncorpharm subsidiary  which had no significant general and administrative expenses in the remainder of the increase of approximately million was primarily due to increased expenses associated with the expansion of the company s marketing and field sales force in north america  beginning in the second half of approximately million of the increase in compared to is attributable to expenses associated with the acquisition of appligene and the integration and consolidation of the company s newly acquired and existing biological imaging businesses 
research and development expenses increased to million in  compared to million in  which represented a increase from million in there was an increase of million in compared to in research and development expenses attributable to the first full year of research and development expenses of appligene and to oncorpharm research expenses 
an increase of million in was due to additional expenditures to support current fda applications for diagnostic products  including the company s her neu genetic test system 
this increase was offset in part by a decrease in the expenditures made for license fees and grants to independent researchers in the acquisition of a sequencing enzyme technology for the detection of subtle genetic mutations accounted for million of the increase in research and development expenses in compared to clinical and regulatory expenses increased to million in  compared to million in  which represented a decrease from million in the increase in clinical and regulatory expenses in compared to was attributable to the substantial regulatory efforts associated with the company s current applications for fda approval of certain diagnostic tests  including her neu 
during  clinical and regulatory expenses were higher than in due to costs associated with clinical trials for the company s genetic test systems for chronic myelogenous leukemia and breast cancer 
write off of acquired research and development projects in process of million in was attributable to the acquisitions of appligene and bds 
investment income decreased to million in  compared to million in  which represented a increase from million in the level of investment income is directly related to the level of investment funds which increased in early with the public offering of common stock and thereafter decreased through operating expenditures 
other expense of million in and million in represents primarily interest expense which has become more significant through the issuance and acquisition of debt related to the businesses acquired in such debt is largely at fixed interest rates 
equity in net loss of affiliate was million in and million in attributable to the company s interest in the losses of its unconsolidated affiliate  oncormed 
the decrease was due to a reduction in the level of the company s interest in the affiliate in late in  the company included in its consolidated loss from operations expenses of million attributable to oncormed 
as a result of the factors discussed above  net loss decreased to million in compared to million in  which represented an increase of from million in the company does not believe that inflation has had a material effect on its results of operations during the last three years 
liquidity and capital resources the cash and liquid investments balances of the company were million at december   compared to million at december  liquid investments include cash equivalents  short term investments and non current fixed income securities investments as set forth on the consolidated balance sheet included elsewhere in this annual report 
the company invests its excess cash exclusively in publicly traded  investment grade  fixed income securities 
the following table sets forth the most significant elements of the cash flows of the company in in millions of dollars net cash used in operating activities proceeds from the sale of common stock and issuance of convertible note payable principal portion of debt repayments net investment in working capital purchase of equipment and leasehold improvements proceeds from exercise of options  long term borrowings and other net decrease in cash and liquid investments the net cash used in operating activities is the result of the losses of the company described in results of operations above in this management s discussion and analysis 
the company s operations in will require the further utilization of significant amounts of cash 
the proceeds of million from the sales of common stock and issuance of convertible note payable were from a private placement of million in december and from sales of common stock of oncorpharm of million in a private placement of preferred stock in april the principal portion of debt service related principally to debt incurred in connection with acquisitions made in and is expected to continue at a reduced rate through the third quarter of the net investment in working capital related to the establishment of base stocks of appligene products in the us and of other new product lines 
purchases of equipment and leasehold improvements were primarily for i construction of the oncorpharm laboratory and ii replacement of communication and data processing systems 
the company expects the level of capital purchases to continue at a reduced rate in the company leases most of its facilities under operating leases with aggregate annual obligations for of million 
the company has committed to expend million in support of various research agreements for the company includes its proportionate share of the losses of oncormed and oncorpharm in its net losses 
losses relating to the activities of oncorpharm and oncormed contributed million and million  respectively  to the net loss in oncorpharm had million of cash included in the company s consolidated cash balance at december  oncorpharm will require additional financing in the near future and may seek additional private equity capital from sources other than the company 
the company does not currently intend to provide a significant portion of such financing although the company may do so 
the company has available approximately million in us income tax net operating loss carryforwards which will significantly reduce any income tax liability which otherwise would be due on profits  if any  earned in the future 
other than as noted above with respect to oncorpharm  the company believes that it has sufficient cash resources for at least the remainder of subsequent event in march  the holders of certain of the company s convertible notes exercised their rights to convert million of principal amount of the notes into common stock of the company at a conversion price of approximately per share 
accordingly  the company issued approximately  registered shares of common stock pursuant to this conversion 

